NCT01782963View on ClinicalTrials.gov

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

DRUG

Bortezomib

DRUG

Dexamethasone

Trial Locations (6)

Unknown

John Hopkins University, Baltimore

02115

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

01923

Massachusetts General Hospital/North Shore Cancer Center, Danvers

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01782963 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter